Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“In 2022, the Biden administration launched an inquiry seeking to reschedule marijuana.”
Mostly supportedConfidence: MODERATE

Reasoning

The provided excerpt explicitly says that in 2022 the Biden administration launched an inquiry seeking to reschedule marijuana. This directly supports the claim. No additional sources were supplied to corroborate or refute the statement, so the assessment is based solely on this evidence.

On confidence: The claim is directly stated in a Tier 1 primary source (Reason article) that reports the Biden administration launched an inquiry in 2022 to reschedule marijuana. No contradictory evidence was found, but verification relies on a single media source.

Important context

The article also mentions that the policy was continued by the Trump administration, which may reflect a timeline inconsistency, but does not affect the core claim about the 2022 Biden inquiry.

Evidence

Supporting (1)

  • Tier 1 — Primary source
    The way the FDA and DEA ban drugs is unaccountable and arbitrary

    shown potential for use in experimental psychology but have to go through lengthy approval processes before they can be used in tests. Reason 's Jacob Sullum has written how the federal ban on MDMA has prevented labs from finalizing…

Limitations

Assessment is limited to the single Reason article; no official government documents or multiple independent reports were consulted. The source’s accuracy cannot be independently confirmed within the provided evidence.

Last verified:
Oct 1, 2026, 4:11 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

The Way the FDA and DEA Ban Drugs Is Unaccountable and Arbitrary

Reason · Ryan Curtis